我国慢性丙型肝炎患者抗病毒治疗现状及药物选择策略分析

肝脏 ›› 2019, Vol. 24 ›› Issue (11): 1230-1233.

我国慢性丙型肝炎患者抗病毒治疗现状及药物选择策略分析

卢捷, 陈立畅, 周惠娟, 谢青, 林兰意

200025 上海交通大学医学院附属瑞金医院感染科

收稿日期:2019-09-22 出版日期:2019-11-25 发布日期:2020-04-01
通讯作者: 林兰意,Email:lanyilin2002@163.com
基金资助:
国家自然科学基金(81501733);国家十三五科技重大专项“艾滋病和病毒性肝炎等重大传染病防治” (2017ZX10302201-004-005);上海市临床重点专科建设项目(感染病学)

Current status of antiviral therapy for chronic HCV infection in China

LU Jie, CHEN Li-chang, ZHOU Hui-juan, XIE Qing, LIN Lan-yi

Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Received:2019-09-22 Online:2019-11-25 Published:2020-04-01
Contact: LIN Lan-yi, Email: lanyilin2002@163.com

摘要/Abstract

摘要： 目的了解我国慢性丙型肝炎患者抗病毒治疗现状。方法选取2017年7月至2019年3月期间于瑞金医院感染科诊治的慢性丙肝患者,收集其临床及实验室数据,分析抗病毒药物选择的影响因素。结果共入组165例,未治疗者25例,聚乙二醇干扰素联合利巴韦林(PR)方案治疗者8例,基因型特异性直接抗病毒药物(DAA)方案者44例,泛基因型DAA方案者85例。除丙通沙是各基因型最常选择的方案以外,基因1b型患者中,选择基因型特异性DAA的比例(40%,44/111)明显高于其他泛基因型药物(7%,8/111)。结论泛基因型DAA治疗是首选,价格是可选范围内除疗效与安全性以外最重要的决定因素。

关键词: 丙型肝炎, 抗病毒治疗, 直接抗病毒药物

Abstract: Objective To investigate the current usage of antiviral therapy in Chinese chronic hepatitis C population.Methods Patients with chronic hepatitis C virus (HCV) infection who visited our department from July 2017 to March 2019 were enrolled. Clinical characteristics and options of antiviral therapy were collected and then analyzed according to current international practice guidelines. Results A total of 165 patients were included, among which 15% (25/165) hadn′t started treatment. Almost 5% (8/165) of them were treated with polyglycol interferon combined ribavirin therapy. The proportions of patients treated with genotype-specific and pan-genotypic direct-acting antiviral agents (DAAs) were 27% (44/165) and 51% (85/165), respectively. Although sofosbuvir/velpatasvir is most popular among patients with all genotypes, genotype-specific DAAs (40%) were used more favorably than pan-genotypic DAAs (7%) among genotype 1b population due to efficacy, safety and most importantly price.Conclusion Pan-genotypic DAAs are recognized as the first-line treatment options among chronic hepatitis C population. Treatment cost, other than efficacy and safety, takes a big part in treatment option.

Key words: Hepatitis C, Antiviral therapy, Direct-acting antiviral agents

卢捷, 陈立畅, 周惠娟, 谢青, 林兰意. 我国慢性丙型肝炎患者抗病毒治疗现状及药物选择策略分析[J]. 肝脏, 2019, 24(11): 1230-1233.

LU Jie, CHEN Li-chang, ZHOU Hui-juan, XIE Qing, LIN Lan-yi. Current status of antiviral therapy for chronic HCV infection in China[J]. Chinese Hepatolgy, 2019, 24(11): 1230-1233.

参考文献

[1] 中华医学会肝病学分会、感染病学分会.丙型肝炎防治指南(2015更新版).肝脏,2015,20:933-949.
[2] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med, 2002, 347:975-982.
[3] Kao JH, Tung SY, Lee Y, et al. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. J Gastroenterol Hepatol, 2016, 31: 1757-1765.
[4] Lawitz E1, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med, 2013, 368:1878-1887.
[5] Kowdley KV, Stuart GC, Reddy RK, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med, 2014, 370:1879-1888.
[6] Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med, 2014, 370:1483-1493.
[7] Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med, 2014, 370:1889-1898.
[8] Karino Y1, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol, 2013, 58:646-654.
[9] Ferenci P1, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med, 2014, 370:1983-1992.
[10] Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype1, 4, or 6 Infection: a randomized trial. Ann Intern Med, 2015, 163:1-13.
[11] Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med, 2014, 370:211-221.
[12] Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med, 2015, 373:2599-2607.
[13] Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med, 2018, 378:354-369.
[14] Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis, 2017, 17:1062-1068.
[15] European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol, 2018, 69:461-511.
[16] Geneva: World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. 2018.
[17] AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis, 2018, 67:1477-1492.